Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.
For a lifelong medication like nilotinib, the daily logistical burden of a strict eating schedule—waiting hours before and after dosing—can be a greater deterrent to patient adherence than the drug's direct pharmacological side effects.
The new nilotinib formulation is unaffected by food, preventing dangerous spikes in drug concentration. This stability may reduce the risk of arterial occlusive events, a major concern with the original drug, which could have been triggered by patients eating too close to their dose.